At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LNAI Lunai Bioworks
Not Yet Opened 04-08 16:00:00 EDT
0.3570
-0.0371
-9.41%
盘后0.3690
+0.0120+3.36%
19:58 EDT
High0.4070Low0.3422Vol7.66M
Open0.3906D1 Closing0.3941Amplitude16.44%
Mkt Cap8.63MTradable Cap5.25MTotal Shares24.19M
T/O2.87MT/O Rate52.12%Tradable Shares14.71M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lunai Bioworks unit BioSymetrics wins first revenue-generating defense collaboration
Reuters  ·  04-07 21:06
Lunai Bioworks unit BioSymetrics wins first revenue-generating defense collaboration
Lunai Bioworks (Nasdaq: Lnai) Secures First Revenue-Generating Defense Collaboration Through Biosymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
THOMSON REUTERS  ·  04-07 21:05
Lunai Bioworks (Nasdaq: Lnai) Secures First Revenue-Generating Defense Collaboration Through Biosymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal
Reuters  ·  03-31
Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal
Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price
Reuters  ·  03-26
Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform for CNS Alzheimer's Therapies With Broad CNS Delivery Applications
THOMSON REUTERS  ·  03-26
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform for CNS Alzheimer's Therapies With Broad CNS Delivery Applications
Lunai Bioworks announces formation of Pathfinder Consortium
TIPRANKS  ·  03-19
Lunai Bioworks announces formation of Pathfinder Consortium
Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months
Reuters  ·  03-19
Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months
Tivic Subsidiary Velocity Bioworks Signs San Antonio Facility Leases
Reuters  ·  03-14
Tivic Subsidiary Velocity Bioworks Signs San Antonio Facility Leases
BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC Filing
Reuters  ·  03-06
BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC Filing
Lunai Bioworks Inc - Implements Temporary Furlough of Employees in US and Canada on Feb 27, 2026 - SEC Filing
THOMSON REUTERS  ·  03-06
Lunai Bioworks Inc - Implements Temporary Furlough of Employees in US and Canada on Feb 27, 2026 - SEC Filing
Lunai Bioworks Inc - CEO and CFO Voluntarily Agree to Temporarily Defer Salary Payments During Furlough - SEC Filing
THOMSON REUTERS  ·  03-06
Lunai Bioworks Inc - CEO and CFO Voluntarily Agree to Temporarily Defer Salary Payments During Furlough - SEC Filing
Lunai Bioworks Furloughs U.S. and Canada Employees
Reuters  ·  03-06
Lunai Bioworks Furloughs U.S. and Canada Employees
Nasdaq Moves to Delist Lunai Bioworks Securities
Reuters  ·  02-24
Nasdaq Moves to Delist Lunai Bioworks Securities
Lunai Bioworks Secures U.S. Patent for AI Debiasing Framework in Drug Discovery
Reuters  ·  02-19
Lunai Bioworks Secures U.S. Patent for AI Debiasing Framework in Drug Discovery
Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY
Benzinga  ·  02-18
Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY
Lunai Bioworks net income loss narrows to USD 1.80 million in Q4, down 75 percent
Reuters  ·  02-18
Lunai Bioworks net income loss narrows to USD 1.80 million in Q4, down 75 percent
Lunai Bioworks CEO Showcases AI Drug Discovery Platform on CNBC
Reuters  ·  02-13
Lunai Bioworks CEO Showcases AI Drug Discovery Platform on CNBC
Nasdaq Moves to Delist Lunai Bioworks for Minimum Bid Price Violation
Reuters  ·  02-13
Nasdaq Moves to Delist Lunai Bioworks for Minimum Bid Price Violation
Lunai Bioworks Unveils AI Platform Targeting Disease Subtypes for Precision Drug Discovery
Reuters  ·  02-10
Lunai Bioworks Unveils AI Platform Targeting Disease Subtypes for Precision Drug Discovery
Lunai Bioworks startet KI-Onkologie-Pilotprojekt mit klinischem Partner
Reuters  ·  02-09
Lunai Bioworks startet KI-Onkologie-Pilotprojekt mit klinischem Partner

Introduction

Company Name.
Lunai Bioworks
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--